Search Results for “Johnson ” – Page 5 – media

Johnson & Johnson’s Darzalex snags landmark myeloma approval in first-line patients

EHR vendor Allscripts has made an agreement to purchase patient communication app maker Health Grid for $60 million in cash, with an additional $50 million in earnout payments based on Health Grid achieving certain revenue targets over the next three years, according to a recently registered SEC filing. The merger of the two companies is expected to close sometime during Q2 2018.
- Source: fiercepharma
- 577
- May 10, 2018
Darzalex Johnson & Johnson myeloma
Johnson & Johnson Medical Devices Companies Acquire Orthotaxy to Develop Next-Generation Robotic-Assisted Surgery Platform in Orthopaedics

Orthotaxy’s Technology Will Be Leveraged to Develop Cost-Effective, Time-Efficient, User-Friendly Offering in a Broad Range of Orthopaedics Procedures.
- Source: Jnj
- 522
- February 27, 2018
Market Views Orthopaedics
Johnson & Johnson Reports 2017 Fourth-Quarter Results

Johnson & Johnson today announced sales of $20.2 billion for the fourth quarter of 2017, an increase of 11.5% as compared to the fourth quarter of 2016. Operational sales results increased 9.4% and the positive impact of currency was 2.1%. Domestic sales increased 9.8%. International sales increased 13.5%, reflecting operational growth of 9.0% and a positive currency impact of 4.5%.
- Source: Johnson & Johnson
- 513
- February 17, 2018
Company Insight Johnson & Johnson
Johnson & Johnson Medical to buy German software firm Surgical Process Institute

Johnson & Johnson Group world wide chair Sandi Peterson said: “At Johnson & Johnson Medical Devices Companies, we are committed to broadening our portfolio of products and services to meet the changing needs of our customers around the world.
- Source: healthcareit.medicaldevices-business-review
- 487
- October 24, 2017
Johnson & Johnson
Pfizer sues Johnson & Johnson, alleging anticompetitive practices to maintain a drug monopoly

A legal brawl between two of the world’s largest drug companies could shape the future of a nascent market of copycat drugs that are intended to bring down the cost of the most advanced and expensive medicines.
- Source: Washingtonpost
- 702
- September 22, 2017
biosimilar Johnson & Johnson Pfizer rheumatoid arthritis
Johnson & Johnson Reports 2017 Second-Quarter Results

New Brunswick, N.J. (July 18, 2017) – Johnson & Johnson (NYSE: JNJ) today announced sales of $18.8 billion for the second quarter of 2017, an increase of 1.9% as compared to the second quarter of 2016. Operational sales results increased 2.9% and the negative impact of currency was 1.0%. Domestic sales increased 1.6%. International sales increased 2.3%, reflecting operational growth of 4.4% and a negative currency impact of 2.1%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 0.5%, domestic sales decreased 1.0% and international sales increased 2.0%.*
- Source: www.jnj.com
- 596
- August 4, 2017
Company Insight
Regeneron’s midlife crisis

Regeneron is a role model for the biotech community. No biotech company wants to be Regeneron. “Becoming China’s Regeneron” is the slogan of many domestic biotechs. However, such a Regeneron cannot escape its midlife crisis. The attack of opponents, the victory of Eylea generic drugs, and the successive blows of dual-antibodies have put Regeneron in an extremely delicate stage. On the one hand, with two blockbuster drugs, Regeneron has completed the transformation from biotech to big pharma. In the first half of the year, its stock price continued to rise, successfully breaking through the $100 billion threshold, and its market value reached $133.2 billion. On the other hand, although the market believes in Regeneron’s R&D and platform technology capabilities, how can a new billion-dollar blockbuster drug be so easy? And Regeneron’s highly anticipated oncology business is not as glamorous as autoimmunity and ophthalmology, and its progress is also lackluster. So ...
- Source: drugdu
- 23
- November 22, 2024
Is Jingtai Technology once again breaking through the “first AI pharmaceutical stock” halo and shedding?

Jingtai Technology, which has the halo of being the “first AI pharmaceutical stock” in China, has attracted considerable attention in the secondary market. In the past few months, it has always sparked discussions within the industry due to occasional breakthroughs. According to Wind, on November 19th, Jingtai Technology’s lowest intraday price was HKD 3.51 per share, hitting a new low since its listing. The closing price for the day was HKD 4.00 per share, a drop of 12.66%. Compared to its issue price of HKD 5.28 per share, it has dropped 24.24%. In fact, since September this year, the stock price of Jingtai Technology has shown an overall fluctuating downward trend. According to the official website of Jingtai Technology, it is an innovative research and development platform company driven by artificial intelligence (AI) and robots. Based on technologies and capabilities such as quantum physics, artificial intelligence, cloud computing, and large-scale ...
- Source: drugdu
- 35
- November 21, 2024
Celltrion expands European market, acquires iQone Healthcare for 30 billion

On Friday, South Korean biosimilar giant Celltrion said it had completed the acquisition of iQone Healthcare Switzerland for approximately 30 billion won (about 155 million yuan) as part of its European expansion strategy. After the acquisition, iQone Healthcare Switzerland will become a wholly-owned subsidiary of Celltrion Healthcare Hungary Kft. The transaction will also provide Celltrion with the opportunity to obtain authorizations, further enhancing its pipeline of innovative therapies. In 2022, iQone’s annual revenue was 18.9 billion won (about 18.9 million US dollars), and sales increased by 57% to 29.6 billion won in 2023. Celltrion said the acquisition will further accelerate the expansion of its prescription drug business in Switzerland. According to IQVIA data, sales performance in the country remains strong, with the Ramsima series (IV and SC) accounting for 61% of the market share in the second quarter of this year. The company noted that its follow-up products are expected ...
- Source: drugdu
- 33
- November 20, 2024
Breaking news! CEO of global orthopedic giant may be dismissed

Recently, according to the British “Mail on Sunday report”, the global orthopedic giant Smith & Nephew has been severely warned by shareholders due to poor performance. Smith & Nephew’s shareholders have lost patience with the strategic development speed of CEO Deepak Nath and declared: If the company’s performance cannot be improved, Deepak Nath will be dismissed, and Smith & Nephew will also face the split of the orthopedic department. It is reported that Smith & Nephew’s stock price has fallen by as much as 44% in the past five years. As this year’s performance has not “cleared up”, shareholders’ emotions are difficult to appease, further putting pressure on Deepak Nath. Smith & Nephew was founded in the UK in 1856. This old company with a long history of more than 100 years has three main businesses: orthopedics, sports medicine and otolaryngology, and advanced wound management. At present, Smith & Nephew ...
- Source: drugdu
- 37
- November 18, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.